asthma
The future’s bright, the future’s digital in drug delivery
As a new era of digital drug delivery is making headway, Dr Steven Wick, vice president, Product Development & Commercialisation, 3M Drug Delivery Systems, gives us his thoughts on this digital future. more
Owlstone Medical signs service agreement with AstraZeneca to identify breath biomarkers
Diagnostics company, Owlstone Medical, has signed a service agreement with global biopharmaceutical company, AstraZeneca, to explore how breath can be used to identify novel biomarkers for personalised medicine applications. more
The top five tweets: From the ‘secret payments’ to asthma — what interested EPM readers this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Dupixent to be reviewed as a potential treatment for inadequately controlled asthma
The European Medicines Agency (EMA) has accepted for review an application for an add-on maintenance treatment in certain adults and adolescents (12 years and older) with inadequately controlled moderate-to-severe asthma, Dupixent (dupilumab). more
Three specific lots of asthma inhalers recalled due to manufacturing issue
A patient and a pharmacy level drug alert recall has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) for three specific lots of asthma inhalers as they may not deliver the full number doses more
The top five tweets: From MedTalk podcast to a lab automation — what are EPM readers viewing this week?
Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more
Phase I trial set to start to evaluate novel asthma treatment
A Phase I study is set to be initiated by OncoArendi Therapeutics to assess the safety, tolerability and pharmacokinetics of its lead compound and novel drug candidate, OATD-01 for the treatment of asthma. more
Propeller and GSK expand digital health collaboration
Digital solution provider for respiratory medicine, Propeller Health, is expanding its digital health collaboration with GlaxoSmithKline (GSK) for the improvement of asthma and chronic obstructive pulmonary disease (COPD) management. more
Keep it simple: Driving growth for inhalers in emerging markets
‘Advanced simplicity’ will drive growth for inhalers in emerging markets, Peter Schmelzer, CEO of H&T Presspart tells us more. more
New form of asthma treatment approved for use on NHS
A new severe asthma treatment, Reslizumab, has been recommended for use on the NHS by the National Institute for Health and Care Excellence (NICE). more
Data extraction could lead to faster drugs, study says
The results from the asthma arm of the world’s first digitally enhanced Randomised Controlled Trial (RCT) have been announced. more
Relvar Ellipta significantly improves asthma control
Positive results from the SLS in asthma have been announced by GSK and Innoviva, demonstrating that patients initiated on treatment with Relvar Ellipta significantly improved asthma control compared with usual care. more
GlaxoSmithKline asthma drug receives NICE approval for NHS
The National Institute for Health and Care Excellence has drawn out guidelines recommending the use of pharma company GlaxoSmtihKline’s (GSK) biologic drug for asthma patients on the NHS in England and Wales. more
Big data and asthma intelligence set to benefit pharmaceutical companies
Pharmaceutical companies set to benefit from intelligence on asthma as Aerobit teams with artificial intelligence experts to unlock the potential of big data. more
Asthmatics to receive targeted treatment
Novartis and the National Institute for Health Research (NIHR) Translational Research Partnership are investigating how omalizumab can be targeted to better treat asthma patients more
GSK receives first FDA approval for injectable asthma drug
GlaxoSmithKline’s (GSK) Nucala is the first anti-interleukin-5 (anti-IL-5) treatment for severe asthma approved by the US Food and Drug Administration (FDA) more
Mylan launches first generic equivalent to GSK's inhaler asthma therapy
Mylan has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the UK. more
Smart work
Aptar Pharma’s Prohaler is a smart DPI that has been developed with the patient in mind. This, says Aptar Pharma, makes it intuitive and simple to use by all asthma and COPD patients more
Asthma treatment getting personal
A new report finds that the latest trials in asthma treatments herald a shift towards a personal, individual approach to therapy. more
A real Pro
Aptar Pharma will unveil its Prohaler — the smart DPI for optimal patient compliance. more
